Table 5. ADP induced platelet aggregation level by CYP2C19*2, *3 and PON1 Q192R polymorphisms in clopidogrel treated patients with coronary artery disease.
| Genotypes | n | Platelet Aggregation Level | |
| CYP2C19 *2 | GG (*1/*1) | 112 | 39.16±23.28 |
| (rs4244285; 681G>A) | GA (*1/*2) | 84 | 45.20±23.62 |
| AA (*2/*2) | 15 | 73.07±39.77 | |
| p-value | 2.98×10−5 | ||
| CYP2C19 *3 | GG (*1/*1) | 197 | 43.10±26.36 |
| (rs4986893; 636G>A) | GA (*1/*3) | 14 | 56.29±20.69 |
| AA (*3/*3) | 0 | - | |
| p-value | 0.069 | ||
| CYP2C19 *2 | *1/*1 | 106 | 38.90±23.49 |
| & CYP2C19 *3 | *1/*2 | 76 | 43.36±23.28 |
| *1/*3 | 6 | 47.67±19.14 | |
| *2/*3 | 8 | 62.75±20.54 | |
| *2/*2 | 15 | 73.07±39.77 | |
| p-value | 1.98×10−6 | ||
| PON1 | GG (RR) | 105 | 42.14±25.43 |
| (rs662; 575A>G) | AG (QR) | 84 | 45.77±27.30 |
| AA (QQ) | 22 | 45.86±26.08 | |
| p-value | 0.359 |
p-values assuming additive genetic model represent the association between genotype and ADP-induced platelet aggregation (U) at p-value<0.05.